By: Rosana Gnanajothy, MD From: medpagetoday.com ASCO’s Clinical Cancer Advances 2020 report highlights some of the important advances made in the treatment of breast cancer within the past year. In 2019, ado-trastuzumab emtansine (T-DM1) was approved in the adjuvant setting for HER2-positive patients with residual disease following neoadjuvant therapy. This was an important development following the findings of the KATHERINE …
-
-
Love After a Breast Cancer Diagnosis
-
Why I Can’t Write Your Breast Cancer Story for You
-
Moving to a Distant Location as a Breast Cancer Survivor
-
Getting a Second Opinion After a Breast Cancer Diagnosis
-
Dealing with the Side Effects of Breast Cancer Treatments
